Drugs that may shape 2017 and the trends molding new-drug discovery






Here’s a look at the drugs that may shape 2017, compliments of FirstWord Pharma. It’s a list of some of the products I agree are likely to dominate industry news… Read more »

Obamacare repeal rushed forward by GOP; realistically, what can we expect next?






House Republicans on Friday (January 13, 2017) took the first step in repealing President Obama’s signature healthcare law with a 227 to 198 vote on a budget resolution passed earlier… Read more »

Valeant divests assets worth $2.1 billion to ease debt load; finally a smart move, but too little, too late?






Valeant Pharmaceuticals International Inc. (Laval Quebec) is selling its Dendreon cancer treatment business and three skincare brands for $2.12 billion as the troubled Canadian drugmaker looks to reduce more than… Read more »

Trump scorns Pharma, calls for drug pricebidding; stocks swoon on latest pivot, but does the POTUS-elect mean it?






President-elect Donald Trump on Wednesday (January 11, 2017) pledged to change the way the federal government purchases prescription drugs, a striking, largely unforseen warning to the drug industry that he… Read more »

Japan’s Takeda leads off 2017 M&A season with gutsy deal to buy US cancer specialist Ariad for $5.2 billion; it’s expensive, but probably worth it






Japan’s Takeda Pharmaceutical Co. Ltd. agreed to acquire Ariad Pharmaceuticals Inc. (Cambridge MA) for $24 per share in cash, or an enterprise value of approximately $5.2 billion, boosting its oncology… Read more »

Biotech predictions for 2017 return to positive fundamentals; 2016 meltdown still in rear-view mirror






The NASDAQ Biotech Index got hammered in 2016–-but mostly due to the market melting in January 2016. The Nasdaq Biotech Index collapsed 28% in the opening weeks of 2016 and… Read more »

GOP keeps promise to begin Obamacare repeal; will Trump’s chameleon stance on universal coverage matter?






With Republican leaders pressing to dismantle the Affordable Care Act, possibly within weeks, moderate Senate Democrats reached out on Thursday to Republicans, appealing for them to slow down the repeal… Read more »

Democrats demand probe into stock trading of Trump’s HHS nominee; GOP’s righteous indignation misplaced, puzzling






Senate Democrats on Thursday (January 5, 2016) demanded an ethics probe into Tom Price, President-elect Donald Trump’s pick for US health secretary, following a report that the fierce Obamacare critic… Read more »

Gilead starts 2017 by snatching Novartis cancer specialist; a harbinger of early (and ferocious) M&A?






Gilead Sciences Inc. (Foster City CA) has poached a top cancer specialist from Swiss drugmaker Novartis AG (Basel) as the US healthcare group sharpens its focus on oncology. Alessandro Riva… Read more »

Healthcare stocks primed for comeback in 2017? Here are Steve’s top picks






The population of the world, and the US and developed nations in particular, is growing and getting older, while the costs of keeping people healthy and living longer are exploding…. Read more »